These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1599 related items for PubMed ID: 7750465
1. Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats. Ke HZ, Simmons HA, Pirie CM, Crawford DT, Thompson DD. Endocrinology; 1995 Jun; 136(6):2435-41. PubMed ID: 7750465 [Abstract] [Full Text] [Related]
2. Effects of droloxifene on prevention of cancellous bone loss and bone turnover in the axial skeleton of aged, ovariectomized rats. Ke HZ, Chen HK, Qi H, Pirie CM, Simmons HA, Ma YF, Jee WS, Thompson DD. Bone; 1995 Nov; 17(5):491-6. PubMed ID: 8579962 [Abstract] [Full Text] [Related]
3. Droloxifene prevents ovariectomy-induced bone loss in tibiae and femora of aged female rats: a dual-energy X-ray absorptiometric and histomorphometric study. Chen HK, Ke HZ, Jee WS, Ma YF, Pirie CM, Simmons HA, Thompson DD. J Bone Miner Res; 1995 Aug; 10(8):1256-62. PubMed ID: 8585430 [Abstract] [Full Text] [Related]
4. Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model. Ke HZ, Chen HK, Simmons HA, Qi H, Crawford DT, Pirie CM, Chidsey-Frink KL, Ma YF, Jee WS, Thompson DD. Bone; 1997 Jan; 20(1):31-9. PubMed ID: 8988345 [Abstract] [Full Text] [Related]
7. Tanshinone prevents cancellous bone loss induced by ovariectomy in rats. Cui L, Wu T, Liu YY, Deng YF, Ai CM, Chen HQ. Acta Pharmacol Sin; 2004 May; 25(5):678-84. PubMed ID: 15132837 [Abstract] [Full Text] [Related]
8. An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. Marie PJ, Hott M, Modrowski D, De Pollak C, Guillemain J, Deloffre P, Tsouderos Y. J Bone Miner Res; 1993 May; 8(5):607-15. PubMed ID: 8511988 [Abstract] [Full Text] [Related]
10. [Piperazinyl estrone prevents bone loss in ovariectomized rats]. Li QN, Weng LL, Huang LF, Hu B, Chen HQ, Zheng H. Yao Xue Xue Bao; 2003 Mar; 38(3):161-4. PubMed ID: 12830707 [Abstract] [Full Text] [Related]
11. Additional weight bearing during exercise and estrogen in the rat: the effect on bone mass, turnover, and structure. Tromp AM, Bravenboer N, Tanck E, Oostlander A, Holzmann PJ, Kostense PJ, Roos JC, Burger EH, Huiskes R, Lips P. Calcif Tissue Int; 2006 Dec; 79(6):404-15. PubMed ID: 17160577 [Abstract] [Full Text] [Related]
12. A nonprostanoid EP4 receptor selective prostaglandin E2 agonist restores bone mass and strength in aged, ovariectomized rats. Ke HZ, Crawford DT, Qi H, Simmons HA, Owen TA, Paralkar VM, Li M, Lu B, Grasser WA, Cameron KO, Lefker BA, DaSilva-Jardine P, Scott DO, Zhang Q, Tian XY, Jee WS, Brown TA, Thompson DD. J Bone Miner Res; 2006 Apr; 21(4):565-75. PubMed ID: 16598377 [Abstract] [Full Text] [Related]
13. Antiosteoporotic activity of echinacoside in ovariectomized rats. Li F, Yang X, Yang Y, Guo C, Zhang C, Yang Z, Li P. Phytomedicine; 2013 Apr 15; 20(6):549-57. PubMed ID: 23428402 [Abstract] [Full Text] [Related]
14. A new vitamin D analog, 2MD, restores trabecular and cortical bone mass and strength in ovariectomized rats with established osteopenia. Ke HZ, Qi H, Crawford DT, Simmons HA, Xu G, Li M, Plum L, Clagett-Dame M, DeLuca HF, Thompson DD, Brown TA. J Bone Miner Res; 2005 Oct 15; 20(10):1742-55. PubMed ID: 16160732 [Abstract] [Full Text] [Related]
15. A comparative study of the bone metabolic response to dried plum supplementation and PTH treatment in adult, osteopenic ovariectomized rat. Smith BJ, Bu SY, Wang Y, Rendina E, Lim YF, Marlow D, Clarke SL, Cullen DM, Lucas EA. Bone; 2014 Jan 15; 58():151-9. PubMed ID: 24125756 [Abstract] [Full Text] [Related]
16. Estrogen supplementation modulates effects of the endocrine disrupting pollutant PCB126 in rat bone and uterus: diverging effects in ovariectomized and intact animals. Lind PM, Eriksen EF, Lind L, Orberg J, Sahlin L. Toxicology; 2004 Jul 01; 199(2-3):129-36. PubMed ID: 15147787 [Abstract] [Full Text] [Related]
17. Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models. Ke HZ, Paralkar VM, Grasser WA, Crawford DT, Qi H, Simmons HA, Pirie CM, Chidsey-Frink KL, Owen TA, Smock SL, Chen HK, Jee WS, Cameron KO, Rosati RL, Brown TA, Dasilva-Jardine P, Thompson DD. Endocrinology; 1998 Apr 01; 139(4):2068-76. PubMed ID: 9528995 [Abstract] [Full Text] [Related]
18. A new selective estrogen receptor modulator, CHF 4227.01, preserves bone mass and microarchitecture in ovariectomized rats. Armamento-Villareal R, Sheikh S, Nawaz A, Napoli N, Mueller C, Halstead LR, Brodt MD, Silva MJ, Galbiati E, Caruso PL, Civelli M, Civitelli R. J Bone Miner Res; 2005 Dec 01; 20(12):2178-88. PubMed ID: 16294271 [Abstract] [Full Text] [Related]
19. Lasofoxifene (CP-336,156), a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat. Ke HZ, Qi H, Crawford DT, Chidsey-Frink KL, Simmons HA, Thompson DD. Endocrinology; 2000 Apr 01; 141(4):1338-44. PubMed ID: 10746637 [Abstract] [Full Text] [Related]
20. A new synthetic steroid, osaterone acetate (TZP-4238), increases cortical bone mass and strength by enhancing bone formation in ovariectomized rats. Fuse H, Fukumoto S, Sone H, Miyata Y, Saito T, Nakayama K, Takahashi H, Matsumoto T, Ogata E. J Bone Miner Res; 1997 Apr 01; 12(4):590-7. PubMed ID: 9101370 [Abstract] [Full Text] [Related] Page: [Next] [New Search]